Recurrent epithelial ovarian cancer and hormone therapy

作     者：Yoshihito Yokoyama Hideki Mizunuma 

作者机构：Department of Obstetrics and Gynecology Hirosaki University Graduate School of Medicine Hirosaki 036-8652 Japan 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2013年第1卷第6期

页      面：187-190页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by The Karoji Memorial Fund of the Hirosaki University Graduate School of Medicine 

主　　题：Recurrent ovarian cancer Hormone therapy Letrozole Anastrozole Tamoxifen Fulvestrant 

摘      要：The role of hormone therapy in the treatment of ovarian cancer is not clear. Data on the efficacy and safety of antiestrogens and aromatase inhibitors in recurrent ovarian cancer have been accumulated through phase Ⅱ clinical studies. Most of these studies were conducted in platinum-resistant recurrent ovarian cancer, and although complete response rates were not high, reported adverse events were low. If administered to patients who are positive for estrogen receptors, hormone therapy may become a viable option for the treatment of recurrent ovarian cancer.